Advanced search
Publication Cover
Future Lipidology Volume 1, 2006 - Issue 6
Journal homepage
229
Views
10
CrossRef citations to date
0
Altmetric
Editorial

Phospholipid-mediated signaling in diseased myocardium

Paramjit TappiaInstitute of Cardiovascular Sciences, Laboratory of Cardiac Membrane Biology, St Boniface General Hospital Research Centre (R3020), 351 Tache Avenue, Winnipeg, Manitoba, R2H 2A6, Canada, Tel.: +1 204 235 3681; Fax.: +1 204 233 6723, E-mail: [email protected]Correspondence[email protected]
,
Tushi SingalLaboratory of Cardiac Membrane Biology,Institute of Cardiovascular Sciences, St Boniface General Hospital Research Center & Department of Physiology, University of Manitoba, Canada, Tel.: +1 204 235 3415; Fax.: +1 204 233 6723, E-mail: [email protected]
,
Melissa DentLaboratory of Cardiac Membrane Biology,Institute of Cardiovascular Sciences, St Boniface General Hospital Research Center & Department of Physiology, University of Manitoba, Canada, Tel.: +1 204 235 3415; Fax.: +1 204 233 6723, E-mail: [email protected]
,
Girma AsemuLaboratory of Clinical Investigation,, Baltimore, Maryland, USA, Tel.: +1 410 558 8441; E-mail: [email protected]
,
Mangat RabbanDepartment of Agricultural, Food & Nutritional Sciences, University of Alberta, Edmonton, Canada, Tel.: +1 780 492 3828; Fax.: +1 780 492 9072, E-mail: [email protected]
&
Dhalla NaranjanLaboratory of Experimental Cardiology, Institute of Cardiovascular Sciences, St Boniface General Hospital Research Center & Department of Physiology, University of Manitoba, Canada, Tel.: +1 204 235 3417; Fax.: +1 204 233 6723, E-mail: [email protected]
Pages 701-717 | Published online: 18 Jan 2017

  • 1. Lamers JMJ, Dekkers DH, Bezstarosti K, Meij JT, van Heugten HA: Occurrence and functions of the phosphatidylinositol cycle in the myocardium. Mol. Cell Biochem. 116, 59–67 (1992).
  • Dhalla NS, Dent MR, Tappia PS, Sethi R, Bartha J, Goyal RK: Subcellular remodeling as a viable target for the treatment of congestive heart failure. J. Cardiovasc. Pharmacol. Ther. 11, 31–45 (2006).
  • Tappia PS, Dent MR, Dhalla NS: Oxidative stress and redox regulation of phospholipase D in myocardial disease. Free Radic. Biol. Med. 41, 349–361 (2006).
  • Tappia PS, Liu SY, Shatadal S, Takeda N, Dhalla NS, Panagia V: Changes in sarcolemmal PLC isoenzymes in postinfarct congestive heart failure: partial correction by imidapril. Am. J. Physiol. Heart Circ. Physiol. 277(1 Pt 2), H40–H49 (1999).
  • Park JB, Kim JH, Kim Y et al.: Cardiac phospholipase D2 localizes to sarcolemmal membranes and is inhibited by -actinin in an ADP-ribosylation factor-reversible manner. J. Biol. Chem. 275(28), 21295–21301 (2000).
  • Wolf RA: Association of phospholipase C- with a highly enriched preparation of canine sarcolemma. Am. J. Physiol. 263, C1021–C1028 (1992).
  • McHowat J, Tappia PS, Liu S, McCrory R, Panagia V: Redistribution and abnormal activity of phospholipase A2 isoenzymes in postinfarct congestive heart failure. Am. J. Physiol. Cell. Physiol. 280(3), C573–C580 (2001).
  • Panagia V, Ou C, Taira Y, Dai J, Dhalla NS: Phospholipase D actvity in subcellular membranes of rat ventricular myocardium. Biochim. Biophys. Acta 1064, 242–250 (1991).
  • Williams SA, Tappia PS, Yu CH, Binaglia L, Panagia V, Dhalla NS: Subcellular alterations in cardiac phospholipase D activity in chronic diabetes. Protaglandins Leukot. Essent. Fatty Acids 57, 95–99 (1997).
  • Cocco L, Martelli AM, Gilmour RS, Rhee SG, Manzoli FA: Nuclear phospholipase C and signaling. Biochim. Biophys. Acta 1530, 1–14 (2001).
  • Cocco L, Faenza I, Fiume R, Maria Billi A, Gilmour RS, Manzoli FA: Phosphoinositide-specific phospholipase C (PI-PLC) 1 and nuclear lipid-dependent signaling. Biochim. Biophys. Acta 1761, 509–521 (2006).
  • McHowat J, Creer MH: Catalytic features, regulation and function of myocardial phospholipase A2. Curr. Med. Chem. Cardiovasc. Hematol. Agents 2, 209–218 (2004).
  • Diaz BL, Arm JP: Phospholipase A2. Prostaglandins Leukot. Essent. Fatty Acids 69, 87–97 (2003).
  • Karliner S: Lysophospholipids and the cardiovascular system. Biochim. Biophys. Acta 1582, 216–221 (2002).
  • Xu YJ, Rathi SS, Chapman DC, Arneja AS, Dhalla NS: Mechanisms of lysophosphatidic acid-induced DNA synthesis in vascular smooth muscle cells. J. Cardiovasc. Pharmacol. 41, 381–387 (2003).
  • Xu Y-J, Saini HK, Cheema SK, Dhalla NS: Mechanisms of lysophosphatidic acidinduced increase in intracellular calcium in vascular smooth muscle cells. Cell Calcium 38, 569–579 (2005).
  • Xu Y-J, Rathi SS, Zhang M, Bhugra P, Dhalla NS: Mechanism of the positive inotropic effect of lysophosphatidic acid in rat heart. J. Cardiovasc. Pharmacol. Therap. 7, 109–115 (2002).
  • Six DA, Dennis EA: The expanding superfamily of phospholipase A2 enzymes: classification and characterization. Biochim. Biophys. Acta 1488, 1–19 (2000).
  • Ohto T, Uozumi N, Hirabayashi T, Shimizu T: Identification of novel cytosolic phospholipase A2s, murine cPLA2 , , and , which form a gene cluster with cPLA2 . J. Biol. Chem. 280, 24576–24583 (2005).
  • Tanaka H, Takeya R, Sumimoto H: A novel intracellular membrane-bound calciumindependent phospholipase A2. Biochem. Biophys. Res. Commun. 272, 320–326 (2000).
  • Dennis EA: Diversity of group types, regulation, and function of phospholipase A2. J. Biol. Chem. 269(18), 13057–13060 (1994).
  • Hirabayashi T, Murayama T, Shimizu T: Regulatory mechanism and physiological role of cytosolic phospholipase A2. Biol. Pharm. Bull. 27(18), 1168–1173 (2004).
  • Stahelin RV, Rafter JD, Das S, Cho W: The molecular basis of differential subcellular localization of C2 domains of protein kinase C- and group IVa cytosolic phospholipase A2. J. Biol. Chem. 278(14), 12452–12460 (2003).
  • Rhee SG: Regulation of phosphoinositidespecific phospholipase C. Annu. Rev. Biochem. 70, 281–312 (2001).
  • Fukami K: Structure, regulation, and function of phospholipase C isozymes. J. Biochem. (Tokyo) 131, 293–299 (2002).
  • Singal T, Dhalla NS, Tappia PS: Phospholipase C may be involved in norepinephrine-induced cardiac hypertrophy. Biochem. Biophys. Res. Commun. 320, 1015–1019 (2004).
  • Lopez I, Mak EC, Ding J, Hamm HE, Lomasney JW: A novel bifunctional phopsholipase C that is regulated by G 12 and stimulates the Ras/mitogen-activated protein kinase pathway. J. Biol. Chem. 276, 2758–2765 (2001).
  • Heredia Mdel P, Delgado C, Pereira L et al.: Neuropeptide Y rapidly enhances Cai 2+ transients and Ca2+ sparks in adult rat ventricular myocytes through Y1 receptor and PLC activation. J. Mol. Cell Cardiol. 38(1), 205–212 (2005).
  • Balogh J, Wihlborg AK, Isackson H et al.: Phospholipase C and cAMP-dependent positive inotropic effects of ATP in mouse cardiomyocytes via P2Y11-like receptors. J. Mol. Cell Cardiol. 39(2), 223–230 (2005).
  • Yin G, Yan C, Berk BC: Angiotensin II signaling pathways mediated by tyrosine kinases. Int. J. Biochem. Cell Biol. 35(6), 780–783 (2003).
  • Malhotra A, Kang BP, Opawumi D, BelizaireW, Meggs LG: Molecular biology of protein kinase C signaling in cardiac myocytes. Mol. Cell Biochem. 25(1), 97–107 (2001).
  • Kamp TJ, Hell JW: Regulation of cardiac L-type calcium channels by protein kinase A and protein kinase C. Circ. Res. 87(2), 1095–1102 (2000).
  • Zhang S, Lin J, Hirano Y, Hiraoka M: Modulation of ICa-L by 1-adrenergic stimulation in rat ventricular myocytes. Can. J. Physiol. Pharmacol. 83 (11), 1015–1024 (2005).
  • Rebecchi MJ, Pentyala SN: Structure, function, and control of phosphoinositidespecific phospholipase C. Physiol. Rev. 80(4), 1291–1335 (2000).
  • Song C, Hu CD, Masago M et al.: Regulation of a novel human phospholipase C, PLC , through membrane targeting by Ras. J. Biol. Chem. 276(4), 2752–2757 (2001).
  • Saunders CM, Larman MG, Parrington J et al.: PLC : a sperm-specific trigger of Ca2+ oscillations in eggs and embryo development. Development 129(15), 3533–3544 (2002).
  • Wing MR, Bourdon DM, Harden TK: PLC- : a shared effector protein in Ras-, Rho-, and G -mediated signaling. Mol. Interv. 3(5), 273–280 (2003).
  • Hwang JI, Oh YS, Shin KJ, Kim H, Ryu SH, Suh PG: Molecular cloning and characterization of a novel phospholipase C, PLC- . Biochem. J. 389(1), 181–186 (2005).
  • Asemu G, Dhalla NS, Tappia PS: Inhibition of PLC improves postischemic recovery in isolated rat heart. Am. J. Physiol. Heart Circ. Physiol. 287(6), H2598–H2605 (2004).
  • Katan M: Families of phosphoinositidespecific phospholipase C: structure and function. Biochim. Biophys. Acta 1436, 5–17 (1998).
  • Rhee SG, Bae YS: Regulation of phosphoinositide-specific phospholipase C isozymes. J. Biol. Chem. 272(24), 15045–15048 (1997).
  • Lee CW, Lee KH, Lee SB, Park D, Rhee SG: Regulation of phospholipase C- 4 by ribonucleotides and the subunit of Gq. J. Biol. Chem. 269, 25335–25338 (1994).
  • Rhee SG, Bae YS: Regulation of phosphoinositide-specific phospholipase C isozymes. J. Biol. Chem. 272, 15045–15048 (1997).
  • Sekiya F, Bae YS, Rhee SG: Regulation of phospholipase C isoenzymes: activation of phospholipase C- in the absence of tyrosine phosphorylation. Chem. Phys. Lipids 98, 3–11 (1999).
  • Im H-J, Russell MA, Feng J-F: Transglutaminase II: a new class of GTPbinding protein with new biological functions. Cell Signal 9, 477–482 (1997).
  • Park H, Park ES, Lee HS, Yun HY, Kwon NS, Baek KJ: Distinct characteristic of G h (transglutaminase II) by compartment: GTPase and transglutaminase activities. Biochem. Biophys. Res. Commun. 284, 496–500 (2001).
  • Yagisawa H, Sakuma K, Paterson HE et al.: Replacements of single basic amino acids in the pleckstrin homology domain of phospholipase C- 1 alter the ligand binding, phospholipase activity and interaction with the plasma membrane. J. Biol. Chem. 273, 417–424 (1998).
  • Tall E, Dorman G, Garcia P et al.: Phosphoinositide binding specificity among phospholipase C isozymes as determined by photo-cross-linking to novel substrate and product analogs. Biochemistry 36, 7239–7248 (1997).
  • Frohman MA, Morris AJ: Phospholipase D structure and regulation. Chem. Phys. Lipids. 98, 127–140 (1999).
  • Yamazaki M, Zhang Y, Watanabe H et al.: Interaction of the small G protein RhoA with the C terminus of human phospholipase D1. J. Biol. Chem. 274(10), 6035–6038 (1999).
  • Dai J, Williams SA, Ziegelhoffer A, Panagia V: Structure–activity relationship of the effect of cis-unsaturated fatty acids on heart sarcolemmal phospholipase D activity. Prostaglandins Leukot. Essent. Fatty Acids 52(2–3), 167–171 (1995).
  • Liu SY, Tappia PS, Dai J, Williams SA, Panagia V: Phospholipase A2-mediated activation of phospholipase D in rat heart sarcolemma. J. Mol. Cell Cardiol. 30(6), 1203–1214 (1998).
  • Colley WC, Sung TC, Roll R et al.: Phospholipase D2, a distinct phospholipase D isoform with novel regulatory properties that provokes cytoskeletal reorganization. Curr. Biol. 7(3), 191–201 (1997).
  • Sadoshima J, Izumo S: Signal transduction pathways of angiotensin II-induced c-fos gene expression in cardiac myocytes in vitro. Roles of phospholipid-derived second messengers. Circ. Res. 73(3), 424–438 (1993).
  • Ye H, Wolf RA, Kurz T, Corr PB: Phosphatidic acid increases in response to noradrenaline and endothelin-1 in adult rabbit ventricular myocytes. Cardiovasc. Res. 28(12), 1828–1834 (1994).
  • Dhalla NS, Xu YJ, Sheu SS, Tappia PS, Panagia V: Phosphatidic acid: a potential signal transducer for cardiac hypertrophy. J. Mol. Cell Cardiol. 29(11), 2865–2871 (1997).
  • Xu YJ, Botsford MW, Panagia V, Dhalla NS: Responses of heart function and intracellular free Ca2+ to phosphatidic acid in chronic diabetes. Can. J. Cardiol. 12(10), 1092–1098. (1996) 58. Xu YJ, Panagia V, Shao Q, Wang X, Dhalla NS: Phosphatidic acid increases intracellular free Ca2+ and cardiac contractile force. Am. J. Physiol. 271(2), H651–H659 (1996).
  • Lamers JM, Eskildsen-Helmond YE, Resink AM et al.: Endothelin-1-induced phospholipase C- and D and protein kinase C isoenzyme signaling leading to hypertrophy in rat cardiomyocytes. J. Cardiovasc. Pharmacol. 26(Suppl. 3), S100–S103 (1995).
  • Martin A, Saqib KM, Hodgkin MN et al.: Role and regulation of phospholipase D signalling. Biochem. Soc. Trans. 25, 1157–1160 (1997).
  • Hodgkin MN, Pettitt TR, Martin A, Michell RH, Pemberton AJ, Wakelam MJ: Diacylglycerols and phosphatidates: which molecular species are intracellular messengers? Trends Biochem. Sci. 23, 200–204 (1998).
  • Ungvari Z, Gupte SA, Recchia FA, Batkai S, Pacher P: Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr. Vasc. Pharmacol. 3(3), 221–229 (2005).
  • Kloner RA, Ellis SG, Lange R, Braunwald E: Studies of experimental coronary artery reperfusion. Effects on infarct size, myocardial function, biochemistry, ultrastructure and microvascular damage. Circulation 68(2 Pt 2), 18–15 (1983).
  • Dhalla NS, Temsah RM, Netticadan T, Sandhu MS: Calcium overload in ischemia/reperfusion injury. In: Heart Physiology and Pathophysiology. Sperelakis N, Kurachi Y, Terzic A, Cohen M (Eds). Academic Press, San Diego, CA, USA 949–965 (2000).
  • Zucchi R, Ronca F, Ronca-Testoni S: Modulation of sarcoplasmic reticulum function: a new strategy in cardioprotection? Pharmacol. Ther. 89, 47–65 (2001).
  • Piper HM, Abdallah Y, Schafer C: The first minutes of reperfusion: a window of opportunity for cardioprotection. Cardiovasc. Res. 61, 365–371 (2004).
  • Dhalla NS, Ziegelhoffer A, Harrow JA: Regulatory role of membrane systems in heart function. Can. J. Physiol. Pharmacol. 55(6), 1211–1234 (1997).
  • Dhalla NS, Das PK, Sharma GP: Subcellular basis of cardiac contractile failure. J.Mol. Cell Cardiol. 10(4), 363–385 (1978).
  • Dhalla NS, Pierce GN, Panagia V, Singal PK, Beamish RE: Calcium movements in relation to heart function. Basic Res. Cardiol. 77(2), 117–139 (1982).
  • Gross GJ, Falck JR, Gross ER, Isbell M, Moore J, Nithipatikom K: Cytochrome P450 and arachidonic acid metabolites: role in myocardial ischemia/reperfusion injury revisited. Cardiovasc. Res. 68(1), 18–25 (2005).
  • Hashizume H, Hoque AN, Magishi K, Hara A, Abiko Y: A new approach to the development of anti-ischemic drugs. Substances that counteract the deleterious effect of lysophosphatidylcholine on the heart. Jpn Heart J. 38, 11–25 (1997).
  • Qiao J, Huang F, Naikawadi RP, Kim KS, Said T, Lum H: Lysophosphatidylcholine impairs endothelial barrier function through the G protein-coupled receptor GPR4. Am. J. Physiol. Lung Cell. Mol. Physiol. 291, L91–L101 (2006).
  • Wang L, Radu CG, Yang LV, Bentolila LA, Riedinger M, Witte ON: Lysophosphatidylcholine-induced surface redistribution regulates signaling of the murine G protein-coupled receptor G2A. Mol. Biol. Cell 16, 2234–2247 (2005).
  • Anderson KE, Dart AM, Woodcock EA: Inositol phosphate release and metabolism during myocardial ischemia and reperfusion in rat heart. Circ. Res. 76, 261–268 (1995).
  • Otani H, Prasad MR, Engelman RM, Otani H, Cordis GA, Das DK: Enhanced phosphodiesteratic breakdown and turnover of phosphoinositides during reperfusion of ischemic rat heart. Circ. Res. 63(5), 930–936 (1988).
  • Moraru II, Jones RM, Popescu LM, Engelman RM, Das DK: Prazosin reduces myocardial ischemia/reperfusion-induced Ca2+ overloading in rat heart by inhibiting phosphoinositide signaling. Biochim. Biophys. Acta 1268(1), 1–8 (1995).
  • Munakata M, Stamm C, Friehs I et al.: Protective effects of protein kinase C during myocardial ischemia require activation of phosphatidyl-inositol specific phospholipase C. Ann. Thorac. Surg. 73(4), 1236–1245 (2002).
  • Kurz T, Schneider I, Tolg R, Richardt G: 1-adrenergic receptor-mediated increase in the mass of phosphatidic acid and 1,2-diacylglycerol in ischemic rat heart. Cardiovasc. Res. 42(1), 48–56 (1999).
  • Schwertz DW, Halverson J: Changes in phosphoinositide-specific phospholipase C and phospholipase A2 activity in ischemic and reperfused rat heart. Basic Res. Cardiol. 87(2), 113–127 (1992).
  • Marsh D: Role of lipids in membrane structures. Curr. Opin. Struc. Biol. 2, 497–502 (1992).
  • Asemu G, Tappia PS, Dhalla NS: Identification of the changes in phospholipase C isozymes in ischemic-reperfused rat heart. Arch. Biochem. Biophys. 411(2), 174–182 (2003). oo First to report differential changes in PLC isozyme activity, protein contents and gene expression in hearts subjected to ischemia-reperfusion. 82. Meij JTA, Suzuki S, Panagia V, Dhalla NS: Oxidative stress modifies the activity of sarcolemmal phospholipase C. Biochim. Biophys. Acta 1199(1), 6–12 (1994).
  • Mesaeli N, Tappia PS, Suzuki S, Dhalla NS, Panagia V: Oxidants depress the synthesis of phosphatidylinositol 4,5-bisphosphate in heart sarcolemma. Arch. Biochem. Biophys. 382(1), 48–56 (2000).
  • Liu S-Y, Yu C-H, Hays J-A, Panagia V, Dhalla NS: Modification of heart sarcolemmal phosphoinositide pathway by lysophosphatidylcholine. Biochim. Biophys. Acta 1349(3), 264–274 (1997).
  • Mangat R, Singal T, Dhalla NS, Tappia PS: Inhibition of phospholipase C 1 augments the decrease in cardiomyocyte viability by H2O2. Am. J. Physiol. Heart Circ. Physiol. 291, H854–H860 (2006).
  • Mozzicato S, Joshi BV, Jacobson KA, Liang BT: Role of direct RhoAphospholipase D1 interaction in mediating adenosine-induced protection from cardiac ischemia. FASEB J. 18(2), 406–408 (2004).
  • Tosaki A, Maulik N, Cordis G, Trifan OC, Popescu LM, Das DK: Ischemic preconditioning triggers phospholipase D signaling in rat heart. Am. J. Physiol. 273(4 Pt 2), H1860–H1866 (1997).
  • Bruhl A, Faldum A, Loffelholz K: Degradation of phosphatidylethanol counteracts the apparent phospholipase D-mediated formation in heart and other organs. Biochim. Biophys. Acta 1633(2), 84–89 (2003).
  • Kurz T, Kemken D, Mier K, Weber I, Richardt G: Human cardiac phospholipase D activity is tightly controlled by phosphatidylinositol 4,5-bisphosphate. J. Mol. Cell Cardiol. 36(2), 225–232 (2004).
  • Asemu G, Dent MR, Singal T, Dhalla NS, Tappia PS: Differential changes in phospholipase D and phosphatidate phosphohydrolase activities in ischemiareperfusion of rat heart. Arch. Biochem. Biophys. 436(1), 136–144 (2005).
  • Ferrari R, Ceconi C, Curello S et al.: Oxygen free radicals and myocardial damage: protective role of thiol-containing agents. Am. J. Med. 91(30), S95–S105 (1991).
  • Ozer MK, Parlakpinar H, Cigremis Y, Ucar M, Vardi N, Acet A: Ischemiareperfusion leads to depletion of glutathione content and augmentation of malondialdehyde production in the rat heart from overproduction of oxidants: can caffeic acid phenethyl ester (CAPE) protect the heart? Mol. Cell Biochem. 273(1–2), 169–175 (2005).
  • Wu G, Fang YZ, Yang S, Lupton JR, Turner ND: Glutathione metabolism and its implications for health. J. Nutr. 134(3), 489–492 (2004).
  • Hurd TR, Costa NJ, Dahm CC, Beer SM, Brown SE, Filipovska A, Murphy MP: Glutathionylation of mitochondrial proteins. Antioxid. Redox. Signal 7(7–8), 999–1010 (2005).
  • Sapirstein A, Spech RA, Witzgall R, Bonventre JV: Cytosolic phospholipase A2 (PLA2), but not secretory PLA2, potentiates hydrogen peroxide cytotoxicity in kidney epithelial cells. J. Biol. Chem. 271(35), 21505–21513 (1996).
  • Lindmar R, Loffelholz K: Phospholipase D in rat myocardium: formation of lipid messengers and synergistic activation by G-protein and protein kinase C. Biochem. Pharmacol. 56(7), 799–805 (1998).
  • Snabaitis AK, Hearse DJ, Avkiran M: Regulation of sarcolemmal Na+/H+ exchange by hydrogen peroxide in adult rat ventricular myocytes. Cardiovasc. Res. 53(2), 470–480 (2002).
  • Purdom S, Chen QM: Epidermal growth factor receptor-dependent and -independent pathways in hydrogen peroxide-induced mitogen-activated protein kinase activation in cardiomyocytes and heart fibroblasts. J. Pharmacol. Exp. Ther. 312(3), 1179–1186 (2005).
  • Nataranjan V, Vepa S, Verma RS, Scribner WM: Role of protein tyrosine phosphorylation in H2O2-induced activation of endothelial cell phopsholipase D. Am. J. Physiol. 27, L400–L408 (1996).
  • Nataranjan V, Shamlal R, Al-Hassani M, Ramasarma T, Ravishankar HN, Scribner WM: Tyrosine kinases and calcium dependent activation of endothelial cell phospholipase D by diperoxovanadate. Mol. Cell Biochem. 183, 113–124 (1998).
  • Oh SO, Hong JH, Kim YR et al.: Regulation of phospholipase D2 by H2O2 in PC12 cells. J. Neurochem. 75, 2445–2454 (2000).
  • Min DS, Kim EG, Exton JH: Involvement of tyrosine phosphorylation and protein kinase C in the activation of phospholipase D by H2O2 in Swiss 3T3 fibroblasts. J. Biol. Chem. 273, 29986–29994 (1998).
  • Min DS, Ahn BH, Jo YH: Differential tyrosine phosphorylation of phospholipase D isozymes by hydrogen peroxide and epidermal growth factor in A431 epidermoid carcinoma cells. Mol. Cell 30, 369–378 (2001).
  • Banno Y, Wang S, Ito Y et al.: Involvement of ERK and p38 MAP kinase in oxidative stress-induced phospholipase D activation in PC12 cells. Neuroreport 12, 2271–2275 (2001).
  • Roy S, Parinandi N, Zeigelstein R et al.: Hyperoxia alters phorbol ester-induced phospholipase D activation in bovine lung microvascular endothelial cells. Antioxid. Redox Signal 5, 217–228 (2003).
  • Taher MM, Mahgoub MA, Abd-Elfattah AS: Redox regulation of signal transduction in vascular smooth muscle cells: thiol oxidizing agents induced phospholipase D. Biochem. Mol. Biol. Int. 46, 619–628 (1998).
  • Parinandi NL, Scribner WM, Vepa S, Shi S, Natarajan V: Phospholipase D activation in endothelial cells is redox sensitive. Antioxid. Redox. Signal 1, 193–210 (1999).
  • Dai J, Meij JTA, Padua RR, Panagia V: Depression of cardiac sarcolemmal phospholipase D activity by oxidantinduced thiol modification. Circ. Res. 71, 970–977 (1992).
  • Dai J, Meij JT, Dhalla V, Panagia V: Involvement of thiol groups in the impairment of cardiac sarcoplasmic reticular phospholipase D activity by oxidants. J. Lipid Mediat. Cell Signal. 11(2), 107–118 (1995).
  • Bruhl A, Hafner G, Loffelholz K: Release of choline in the isolated heart, an indicator of ischemic phospholipid degradation and its protection by ischemic preconditioning: no evidence for a role of phospholipase D. Life Sci. 75, 1609–1620 (2004).
  • Moolenaar WH: Lysophospholipids in the limelight: autotaxin takes center stage. J. Cell Biol. 158, 197–199 (2002).
  • Xie Y, Meier KE: Lysophospholipase D and its role in LPA production. Cell Signal. 16, 975–981 (2004).
  • Olivetti G, Abbi R, Quaini F et al.: Apoptosis in the failing human heart. N. Engl. J.Med. 336(16), 1131–1141 (1997).
  • Nishio Y, Kashiwagi A, Taki H et al.: Altered activities of transcription factors and their related gene expression in cardiac tissues of diabetic rats. Diabetes 47(8), 1318–1325 (1998).
  • Bromme HJ, Holtz J: Apoptosis in the heart: when and why? Mol. Cell Biochem. 261–275 (1996).
  • Tritto I, Ambrosio G: Role of oxidants in the signaling pathway of preconditioning. Antioxid. Redox. Signal. 3(1), 3–10 (2001).
  • Dhalla NS, Liu X, Panagia V, Takeda N: Subcellular remodeling and heart dysfunction in chronic diabetes. Cardiovasc. Res. 40(2), 239–247 (1998).
  • Moraru II, Popescu LM, Maulik N, Liu X, Das DK: Phospholipase D signaling in ischemic heart. Biochim. Biophys. Acta 1139(1–2), 148–154 (1992).
  • Cohen MV, Liu Y, Liu GS et al.: Phospholipase D plays a role in ischemic preconditioning in rabbit heart. Circulation 94(7), 1713–1718 (1996).
  • Eskildsen-Helmond YE, Gho BC, Bezstarosti K et al.: Exploration of the possible roles of phospholipase D and protein kinase C in the mechanism of ischemic preconditioning in the myocardium. Ann. NY Acad. Sci. 793, 210–225 (1996).
  • Trifan OC, Popescu LM, Tosaki A, Cordis G, Das DK: Ischemic preconditioning involves phospholipase D. Ann. NY Acad. Sci. 793, 485–488 (1996).
  • Dorn GW 2nd, Force T: Protein kinase cascades in the regulation of cardiac hypertrophy. J. Clin. Invest. 115(3), 527–537 (2005).
  • Kawaguchi H, Sano H, Iizuka K et al.: Phosphatidylinositol metabolism in hypertrophic rat heart. Circ. Res. 72(5), 966–972 (1993).
  • Wang H, Oestreich EA, Maekawa N et al.: Phospholipase C modulates -adrenergic receptor-dependent cardiac contraction and inhibits cardiac hypertrophy. Circ. Res. 97(112), 1305–1313 (2005).
  • Sakata Y: Tissue factors contributing to cardiac hypertrophy in cardiomyopathic hamsters (BIO14.6): involvement of transforming growth factor- 1 and tissue renin-angiotensin system in the progression of cardiac hypertrophy. Hokkaido Igaku Zasshi 68(1), 18–28 (1993).
  • Bai H, Wu LL, Xing DQ, Liu J, Zhao YL: Angiotensin II induced upregulation of G q/11, phospholipase C 3 and extracellular signal-regulated kinase 1/2 via angiotensin II type 1 receptor. Chin. Med. J. (Engl). 117(1), 88–93 (2004).
  • Dent MR, Dhalla NS, Tappia PS: Phospholipase C gene expression, protein content, and activities in cardiac hypertrophy and heart failure due to volume overload. Am. J. Physiol. Heart Circ. Physiol. 287(2), H719–H727 (2004).
  • Dent MR, Aroutiounova N, Dhalla NS, Tappia PS: Losartan attenuates phospholipase C isozyme gene expression in hypertrophied hearts due to volume overload. J. Cell. Mol. Med. (2006) (In Press).
  • Jalili T, Takeishi Y, Song G, Ball NA, Howles G, Walsh RA: PKC translocation without changes in G q and PLC- protein abundance in cardiac hypertrophy and failure. Am. J. Physiol. 277(6 Pt 2), H2298–H2304 (1999).
  • Barac YD, Zeevi-Levin N, Yaniv G et al.: The 1,4,5-inositol trisphosphate pathway is a key component in Fas-mediated hypertrophy in neonatal rat ventricular myocytes. Cardiovasc. Res. 68(1), 75–86 (2005).
  • Peivandi AA, Huhn A, Lehr HA et al.: Upregulation of phospholipase D expression and activation in ventricular pressureoverload hypertrophy. J. Pharmacol. Sci. 98(3), 244–254 (2005).
  • Tappia PS, Yu CH, Di Nardo P, Pasricha AK, Dhalla NS, Panagia V: Depressed responsiveness of phospholipase C isoenzymes to phosphatidic acid in congestive heart failure. J. Mol. Cell Cardiol. 33(3), 431–440 (2001).
  • Henry RA, Boyce SY, Kurz T, Wolf RA: Stimulation and binding of myocardial phospholipase C by phosphatidic acid. Am. J. Physiol. 269, C349-C358 (1995).
  • D’Angelo DD, Sakata Y, Lorenz JN et al.: Transgenic G q overexpression induces cardiac contractile failure in mice. Proc. Natl Acad. Sci. USA 94(15), 8121–8126 (1997).
  • Sakata Y, Hoit BD, Liggett SB, Walsh RA, Dorn GW 2nd: Decompensation of pressure-overload hypertrophy in G q-overexpressing mice. Circulation 97(15), 1488–1495 (1998).
  • Paradis P, Dali-Youcef N, Paradis FW, Thibault G, Nemer M: Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc. Natl Acad. Sci. USA 97(2), 931–936 (2000).
  • Milano CA, Dolber PC, Rockman HA et al.: Myocardial expression of a constitutively active 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc. Natl Acad. Sci. USA 91(21), 10109–10113 (1994).
  • Hefti MA, Harder BA, Eppenberger HM, Schaub MC: Signaling pathways in cardiac myocyte hypertrophy. J. Mol. Cell Cardiol. 29(11), 2873–2892 (1997).
  • Singal T, Dhalla NS, Tappia PS: Norepinephrine-induced changes in gene expression of phospholipase C in cardiomyocytes. J. Mol. Cell Cardiol. 41(1), 126–137 (2006).
  • Schnabel P, Mies F, Nohr T, Geisler M, Bohm M: Differential regulation of phospholipase C- isozymes in cardiomyocyte hypertrophy. Biochem. Biophys. Res. Commun. 275(1), 1–6 (2000).
  • Ju H, Zhao S, Tappia PS, Panagia V, Dixon IM: Expression of Gq and PLC- in scar and border tissue in heart failure due to myocardial infarction. Circulation 97(9), 892–899 (1998).
  • Ziegelhoffer A, Tappia PS, Mesaeli N, Sahi N, Dhalla NS, Panagia V: Low level of sarcolemmal phosphatidylinositol 4,5-bisphosphate in cardiomyopathic hamster (UM-X7.1) heart. Cardiovasc. Res. 49(1), 118–126 (2001).
  • Huang CL, Feng S, Hilgemann DW: Direct activation of inward rectifier potassium channels by PIP2 and its stabilization by G . Nature 391(6669), 803–806 (1998).
  • Caroni P, Zurini M, Clark A: The calcium-pumping ATPase of heart sarcolemma. Ann. NY Acad. Sci. 402, 402–421 (1982).
  • Hilgemann DW, Ball R: Regulation of cardiac Na+, Ca2+ exchange and KATP potassium channels by PIP2. Science 273(5277), 956–959 (1996).
  • Dent MR, Singal T, Dhalla NS, Tappia PS: Expression of phospholipase D isozymes in scar and viable tissue in congestive heart failure due to myocardial infarction. J. Cell. Mol. Med. 8(4), 526–536 (2004).
  • Tappia PS, Maddaford TG, Hurtado C, Panagia V, Pierce GN: Depressed phosphatidic acid-induced contractile activity of failing cardiomyocytes. Biochem. Biophys. Res. Commun. 300(2), 457–463 (2003). , Liu SY, Takeda N, Dhalla NS: Alterations of sarcolemmal phospholipase D and phosphatidate phosphohydrolase in congestive heart failure. Biochim. Biophys. Acta 1584(1), 65–72 (2002).
  • McHowat J, Creer MH, Hicks KK, Jones JH, McCrory R, Kennedy RH: Induction of Ca-independent PLA2 and conservation of plasmalogen polyunsaturated fatty acids in diabetic heart. Am. J. Physiol. Endocrinol. Metab. 279(1), E25–E32 (2000).
  • Su X, Han X, Mancuso DJ, Abendschein DR, Gross RW: Accumulation of long-chain acylcarnitine and 3-hydroxy acylcarnitine molecular species in diabetic myocardium: identification of alterations in mitochondrial fatty acid processing in diabetic myocardium by shotgun lipidomics. Biochemistry 44(13), 5234–5245 (2005).
  • Vecchini A, Del Rosso F, Binaglia L, Dhalla NS, Panagia V: Molecular defects in sarcolemmal glycerophospholipid subclasses in diabetic cardiomyopathy. J. Mol. Cell Cardiol. 32(6), 1061–1074 (2000).
  • Malhotra A, Reich D, Reich D et al.: Experimental diabetes is associated with functional activation of protein kinase C and phosphorylation of troponin I in the heart, which are prevented by angiotensin II receptor blockade. Circ. Res. 81(6), 1027–1033 (1997).
  • Malhotra A, Kang BP, Cheung S, Opawumi D, Meggs LG: Angiotensin II promotes glucose-induced activation of cardiac protein kinase C isozymes and phosphorylation of troponin I. Diabetes 50(8), 1918–1926 (2001).
  • Xiang H, McNeill JH: Protein kinase C activity is altered in diabetic rat hearts. Biochem. Biophys. Res. Commun. 187(2), 703–710 (1992).
  • Tanaka Y, Kashiwagi A, Ogawa T et al.: Effect of verapamil on cardiac protein kinase C activity in diabetic rats. Eur. J. Pharmacol. 200(2–3), 353–356 (1991).
  • Liu X, Wang J, Takeda N, Binaglia L, Panagia V, Dhalla NS: Changes in cardiac protein kinase C activities and isozymes in streptozotocin-induced diabetes. Am. J. Physiol. 277(5 Pt 2), E798–E804 (1999).
  • Wald M, Borda ES, Sterin-Borda L: -adrenergic supersensitivity and decreased number of -adrenoceptors in heart from acute diabetic rats. Can. J. Physiol. Pharmacol. 66(9), 1154–1160 (1988).
  • Tappia PS, Liu S-Y, Tong Y, Ssenyange S, Panagia V: Reduction of phosphatidyliositol-4,5-bisphosphate mass in heart sarcolemma during diabetic cardiomyopathy. Adv. Exp. Med. Biol. 498, 183–190 (2001).
  • Tappia PS, Maddaford TG, Hurtado C et al.: Defective phosphatidic acidphospholipase C signaling in diabetic cardiomyopathy. Biochem. Biophys. Res. Commun. 316(1), 280–289 (2004).
  • Tappia PS, Asemu G, Aroutiounova N, Dhalla NS: Defective sarcolemmal phospholipase C signaling in diabetic cardiomyopathy. Mol. Cell Biochem. 261(1–2), 193–199 (2004).
  • Heyliger CE, Pierce GN, Singal PK, Beamish RE, Dhalla NS: Cardiac - and -adrenergic receptor alterations in diabetic cardiomyopathy. Basic Res. Cardiol. 77(16), 610–618 (1982).
  • Heijnis JB, van Zwieten PA: Enhanced inotropic responsiveness to 1-adrenoceptor stimulation in isolated working hearts from diabetic rats. J. Cardiovasc. Pharmacol. 20(4), 559–562 (1992).
  • Puceat M, Vassort G: Signalling by protein kinase C isoforms in the heart. Mol. Cell Biochem. 157(1–2), 65–72 (1996).
  • Tamada A, Hattori Y, Houzen H et al.: Effects of -adrenoceptor stimulation on contractility, [Ca2+]i, and Ca2+ current in diabetic rat cardiomyocytes. Am. J. Physiol. 274(6 Pt 2), H1849–H1857 (1998).
  • Ha T, Kotsanas G, Wendt I: Intracellular Ca2+ and adrenergic responsiveness of cardiac myocytes in streptozotocin-induced diabetes. Clin. Exp. Pharmacol. Physiol. 26(4), 347–353 (1999).
  • Tong Y, Liu S-Y, Tappia PS, Panagia V: Sarcolemmal PLC 1 is hypoactive but hyperresponsive to phosphatidic acid in diabetic cardiomyopathy. J. Mol. Cell Cardiol. 30, A257 (1998) 167. Tappia PS, Bibeau M, Sahi N, Pierce GN, Dixon IMC, Panagia V: Defective sarcolemmal Gq /PLC 1 signaling in diabetic cardiomyopathy. J. Mol. Cell Cardiol. 32, A46 (2000).
  • Williams SA, Tappia PS, Yu CH, Bibeau M, Panagia V: Impairment of the sarcolemmal phospholipase D-phosphatidate phosphohydrolase pathway in diabetic cardiomyopathy. J. Mol. Cell Cardiol. 30(1), 109–118 (1998).
  • Okumura K, Akiyama N, Hashimoto H, Ogawa K, Satake T: Alteration of 1,2-diacylglycerol content in myocardium from diabetic rats. Diabetes 37(9), 1168–1172 (1988).
  • Inoguchi T, Battan R, Handler E, Sportsman JR, Heath W, King GL: Preferential elevation of protein kinase C isoform II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc. Natl Acad. Sci. USA 89(22), 11059–11063 (1992).
  • Das S, Rand RP: Diacylglycerol causes major structural transitions in phospholipid bilayer membranes. Biochem. Biophys. Res. Commun. 124(2), 491–496 (1984).
  • Das S, Rand RP: Modification by diacylglycerol of the structure and interaction of various phospholipid bilayer membranes. Biochemistry 25(10), 2882–2889 (1986).
  • Meij JT, Suzuki S, Panagia V, Dhalla NS: Oxidative stress modifies the activity of cardiac sarcolemmal phospholipase C. Biochim. Biophys. Acta 1199(1), 6–12 (1994).
  • Pang Y, Bounelis P, Chatham JC, Marchase RB: Hexosamine pathway is responsible for inhibition by diabetes of phenylephrine-induced inotropy. Diabetes 53(4), 1074–1081 (2004).
  • Squadrito G, Cucinotta D: The late complications of diabetes mellitus. Ann. Ital. Med. Int. 6, 126–136 (1991).
  • Bell DSH: Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease. Diabetes Care 18, 708–714 (1995).
  • Rossi E: Cardiovascular disease in diabetes and operative risk. Rays 22, 595–602 (1997).
  • Bell DSH: Diabetic cardiomyopathy. Diabetes Care 26, 2949–2951 (2003).
  • Giles TD: The patients with diabetes mellitus and heart failure: at risk issues. Am. J. Med. 115, S107–S110 (2003).
  • Srikanthan P, Hsueh W: Preventing heart failure inpatients with diabetes. Med. Clin. North Am. 88, 1237–1256 (2004).
  • Langford MC: Type 2 diabetes and chronic systolc heart failure: clinical implications. J. Cardiovasc. Nurs. 19, S35–S44; quiz S45–S46 (2004).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.